Assignee
SANEGENE BIO USA INC
US·1 granted patent·18 pending applications·0 citations·filing 2022–2025
Top patents by PatentIndex Score
19 records- 0169US2024301421A1Small interfering rna targeting c3 and uses thereofSANEGENE BIO USA INC·Filed 2024·Application pending·0 cites
- 0269US2025059540A1Double stranded rna targeting angiopoietin-like 3 (angptl-3) and methods of use thereofSANEGENE BIO USA INC·Filed 2024·Application pending·0 cites
- 0367US2026021188A11'-alkyl modified ribose derivatives and methods of useSANEGENE BIO USA INC·Filed 2025·Application pending·0 cites
- 0467US2024175026A1Small interfering rna targeting c3 and uses thereofSANEGENE BIO USA INC·Filed 2023·Application pending·0 cites
- 0563US12465647B21′-alkyl modified ribose derivatives and methods of useSANEGENE BIO USA INC·Filed 2022·Granted Nov 11, 2025·0 cites·25 claims
- 0663US2025027089A1Double stranded rna targeting proprotein convertase subtilisin kexin 9 (pcsk9) and methods of use thereofSANEGENE BIO USA INC·Filed 2024·Application pending·0 cites
- 0762US2024294916A1Small interfering rna targeting cfb and uses thereofSANEGENE BIO USA INC·Filed 2024·Application pending·0 cites
- 0862US2024309380A1Small interfering rna targeting apoc3 and uses thereofSANEGENE BIO USA INC·Filed 2024·Application pending·0 cites
- 0962US2023159930A1Double stranded rna targeting angiopoietin-like 3 (angptl-3) and methods of use thereofSANEGENE BIO USA INC·Filed 2022·Application pending·0 cites
- 1060US2024052348A1Double stranded rna targeting angiotensinogen (agt) and methods of use thereofSANEGENE BIO USA INC·Filed 2023·Application pending·0 cites
- 1159US2024218363A1Optimized 2'- modified ribose derivatives and methods of useSANEGENE BIO USA INC·Filed 2023·Application pending·0 cites
- 1259US2025064939A1Lipid-based enhancement agent for rna delivery and therapySANEGENE BIO USA INC·Filed 2024·Application pending·0 cites
- 1358US2025018045A1Lipid-based conjugates for systemic, central nervous system, peripheral nervous system, and ocular deliverySANEGENE BIO USA INC·Filed 2024·Application pending·0 cites
- 1458US2024002857A1Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereofSANEGENE BIO USA INC·Filed 2023·Application pending·0 cites
- 1556US2026041779A1Nucleotide-based enhancement agent for rna delivery and therapySANEGENE BIO USA INC·Filed 2023·Application pending·0 cites
- 1654US2023227480A1Polyhydroxylated cyclopentane derivatives and methods of useSANEGENE BIO USA INC·Filed 2022·Application pending·0 cites
- 1754US2023346819A15'-modified carbocyclic ribonucleotide derivatives and methods of useSANEGENE BIO USA INC·Filed 2023·Application pending·0 cites
- 1851US2023241224A12'-alkyl or 3'- alkyl modified ribose derivatives and methods of useSANEGENE BIO USA INC·Filed 2022·Application pending·0 cites
- 1950US2025382616A1Small interfering rna targeting cfb and uses thereofSANEGENE BIO USA INC·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SANEGENE BIO USA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →